Detail

Study ID: SH ARGOS

Title:

Autoantibody Response Guided by immuno-Oncology Surveillance (ARGOS): Repository of blood and tissue for identification of prognostic biomarkers for cancer patients who undergo immuno-oncology therapies

Description:
Title: SH ARGOS: Autoantibody Response Guided by immuno-Oncology Surveillance (Repository of blood, tissue and stool samples for identification of prognostic biomarkers for cancer patients who undergo immuno-oncology therapies); Description: Treatment of cancer patients with immuno-oncology agents has shown promising clinical outcomes for some patients. Some individuals have little to no side effects from their treatment and others develop autoimmune-related side effects. The goal of this study is to generate a collection of blood, tissue and stool samples to study various biomarkers. Biomarkers are parts or products of cells in the blood, tissue and stool of an individual that are strongly associated with the disease. One use for the samples collected from this study is to identify new blood, tissue and stool biomarkers to predict which patients will likely respond to the immuno-oncology therapies.
Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region, Thief River Falls, Worthington
Principal Investigator:
Kristi Egland
Disease:
Cancer Control
Stage:
Unknown
Status:
Active - Open to Accrual